Lower Risk of Incident Cataracts and Diabetic Retinopathy amongst Individuals Treated with Sodium Glucose Cotransporter-2 Inhibitor Compared to Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Mellitus - Goh, Li Yen; Chou, Oscar Hou In; Lee, Sharen; Lee, Teddy Tai Loy; Hui, Jeremy Man To; Him, Hugo Pui Hok; Wong, Wing Tak; Chang, Carlin; Cheung, Bernard Man Yung; Tse, Gary; Zhou, Jiandong (medRxiv, 2024)
Background/Aims Type 2 diabetes mellitus (T2DM) is an extremely prevalent disease with multisystem complications. We aim to compare the effects of two common glucose lowering medications; sodium glucose co-transporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I), on the incidence of diabetic retinopathy and cataracts in T2DM patients in Hong Kong.Methods Retrospective population-based cohort study of T2DM patients treated with SGLT2I or DPP4I between 1st January 2015 and 31st December 2020. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I users was performed on demographics, past co-morbidities, number of prior hospitalizations, duration from T2DM diagnosis to intial drug exposure, non-SGLT2I/DPP4I medications (including other anti-diabetes drugs), abbreviated modification of diet in renal disease, HbA1c, fasting glucose, and their time-weighted means. Sensitivity analysis using a one-year lag time and competing risk analyses using cause-specific and sub-distribution hazard models were conducted.Results This study cohort included 26 165 SGLT2I and 42 796 DPP4I users (total: N=68 961 patients; 56.43% males, median age: 62.0 years old (standard deviation (SD): 12.8)). Over a median follow-up of 5.56 years (IQR: 5.24-5.80) and after propensity score matching (SGLT2I: N=26 165; DPP4I: N=26 165), SGLT2I users had lower incidences of cataract (4.54% vs. 6.64%%, standardised mean difference [SMD]=0.09) and diabetic retinopathy (3.65 vs. 6.19, SMD=0.12) compared to DPP4I users. SGLT2I use was associated with lower risks of new onset cataract (HR: 0.67, 95% CI: [0.62– 0.72] P<0.0001) and diabetic retinopathy (hazard ratio [HR]: 0.57, 95% confidence interval [CI]: [0.53–0.62], P<0.0001). These associations remained significant on multivariable Cox regression ;cataract: HR: 0.69, 95% CI: 0.64–0.75 (P<0.0001); diabetic retinopathy: HR: 0.68, 95% CI: 0.63–0.75 (P<0.0001).Conclusions Amongst T2DM patients in Hong Kong, SGLT2I use was associated with lower risks of new onset cataract or diabetic retinopathy compared to DPP4I use.Synopsis/Precis Sodium glucose cotransporter-2 inhibitor (SGLT2I) use was associated with lower rates of new onset diabetic retinopathy and cataracts compared to dipeptidyl peptidase-4 inhibitor (DPP4I) use in patients with type 2 diabetes melllitus (T2DM) from Hong Kong.What is already known on this topic Various glucose lowering medications may have additional beneficial or aggravating properties for/against diabetic retinopathy and cataract formation in diabetic populations beyond their glucose lowering capabilities.What this study adds This study showed that SGLT2I use was associated with significantly lower rates of new onset cataracts and diabetic retinopathy when compared to DPP4I use in a T2DM population in Hong Kong. Additionally, to the best of our knowledge, this is the first population-based study on the effects of SGLT2I and DPP4I use on the development of cataracts in individuals with T2DM.How this study might affect research, practice or policy This study provides preliminary data for further evaluation of SGLT2I and DPP4I use in preventing the incidence and progression of cataracts and diabetic retinopathy in a T2DM individuals. This study may also aid clinicians in deciding between SGLT2 and DPP4I if microvascular retinal complications and cataracts are a concern in individual cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and complied with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes